Literature DB >> 17462866

Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone.

P C Casarotto1, R Andreatini.   

Abstract

The present study was designed to assess the effect of dexamethasone, a synthetic glucocorticoid receptor agonist, in the sucrose preference test in rats. Rats treated acutely with dexamethasone (5-10 mg/kg) showed a significant decrease in sucrose preference (anhedonia) in comparison to vehicle treated rats, although 1 mg/kg dexamethasone did not alter the sucrose preference. Daily paroxetine treatment (10 g/kg, i.p., 14 days) reversed the anhedonic effect of acute dexamethasone (5 mg/kg), while causing no increased sucrose preference in rats that received dexamethasone vehicle. The paroxetine vehicle treated rats showed anhedonia even 14 days after acute dexamethasone administration. Paroxetine (10 mk/kg, i.p. for 28 days) also reversed anhedonia induced by chronic mild stress (8 weeks). In conclusion, acute dexamethasone induced an enduring anhedonic state that was reversed by repeated paroxetine treatment. Thus, the present study adds new data to the evidence supporting an important role for glucocorticoid in depression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462866     DOI: 10.1016/j.euroneuro.2007.03.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  27 in total

1.  Activation of Brain Indoleamine-2,3-dioxygenase Contributes to Depressive-Like Behavior Induced by an Intracerebroventricular Injection of Streptozotocin in Mice.

Authors:  Leandro Cattelan Souza; Cristiano R Jesse; Marcelo Gomes de Gomes; Lucian Del Fabbro; André Tiago Rossito Goes; Franciele Donato; Silvana Peterini Boeira
Journal:  Neurochem Res       Date:  2017-06-19       Impact factor: 3.996

2.  Investigating dopamine and glucocorticoid systems as underlying mechanisms of anhedonia.

Authors:  Steven J Lamontagne; Sofia I Melendez; Mary C Olmstead
Journal:  Psychopharmacology (Berl)       Date:  2018-08-22       Impact factor: 4.530

3.  Dysregulation of vitamin D metabolism in the brain and myocardium of rats following prolonged exposure to dexamethasone.

Authors:  Pei Jiang; Ying Xue; Huan-De Li; Yi-Ping Liu; Hua-Lin Cai; Mi-Mi Tang; Li-Hong Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-01-22       Impact factor: 4.530

4.  The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice.

Authors:  Or Burstein; Ravid Doron
Journal:  J Vis Exp       Date:  2018-10-24       Impact factor: 1.355

5.  Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice.

Authors:  John Wong; Lisa T Tran; Kaari A Lynch; Lisa J Wood
Journal:  Cancer Biol Ther       Date:  2017-12-12       Impact factor: 4.742

6.  Increased expression level of corticotropin-releasing hormone in the amygdala and in the hypothalamus in rats exposed to chronic unpredictable mild stress.

Authors:  Shan-Shan Wang; Xue-Bo Yan; Michel A Hofman; Dick F Swaab; Jiang-Ning Zhou
Journal:  Neurosci Bull       Date:  2010-08       Impact factor: 5.203

Review 7.  Experimental psychiatric illness and drug abuse models: from human to animal, an overview.

Authors:  Scott Edwards; George F Koob
Journal:  Methods Mol Biol       Date:  2012

Review 8.  HPA Axis Interactions with Behavioral Systems.

Authors:  Amy E B Packard; Ann E Egan; Yvonne M Ulrich-Lai
Journal:  Compr Physiol       Date:  2016-09-15       Impact factor: 9.090

9.  Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: an approach using behavioral tests.

Authors:  Yeshwant Kurhe; Radhakrishnan Mahesh; Deepali Gupta
Journal:  Neurochem Res       Date:  2014-05-11       Impact factor: 3.996

10.  Evaluation of the repeated open-space swim model of depression in the mouse.

Authors:  Eric A Stone; Yan Lin; David Quartermain
Journal:  Pharmacol Biochem Behav       Date:  2008-07-19       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.